Exclusive: Blackstone, Taisho Pharma among final bidders for Takeda's Japan OTC unit - sources
Exclusive: Blackstone, Taisho Pharma among final bidders for Takeda's Japan OTC unit - sources
By Junko Fujita and Rocky Swift
由藤田順子和洛基·斯威夫特
TOKYO (Reuters) - Blackstone, Bain Capital and Taisho Pharmaceutical are among the final bidders for Takeda Pharmaceutical's consumer drug business in Japan, a deal that could be worth up to 400 billion yen ($3.7 billion), three people familiar with the deal said.
東京（路透社）-黑石，貝恩資本和大正製藥是武田製藥在日本的消費藥品業務的最終投標者之一，這筆交易可能價值高達 400 億日元（37 億美元），三人熟悉該交易。
Japan's Taisho Pharmaceutical Holdings Co Ltd is the front runner for the deal, all three people said. CVC Capital Partners is also among the final bidders, they said.
三個人說，日本的大正製藥控股有限公司是該交易的領先者。他們說，CVC 資本合作夥伴也是最終投標者之一。
The sale of Takeda Consumer Healthcare Co, known for its Alinamin line of energy drinks, is part of Takeda's efforts to shed $10 billion in non-core assets to reduce debt following its $59 billion purchase of Shire Plc.
武田消費者保健公司（以 Aleinamin 能量飲料系列而聞名）的出售是武田在購買 590 億美元以減少債務之後努力擺脫 100 億美元的非核心資產以減少債務的一部分 希爾公司。
That deal amount might fall to around 340 billion yen because Blackstone Group and the private equity firms consider the price too high, said two of those people. Taisho could go as high as 400 billion yen, they said.
這筆交易金額可能會下降到 340 億日元左右，因為 黑石集團 這兩個人說，私募股權公司認為價格太高。他們說，大正可能高達 4000 億日元。
Blackstone, Takeda, Taisho and Bain declined to comment. CVC was not immediately available for comment.
黑石，竹田，大正和貝恩拒絕發表評論。CVC 沒有立即可用於評論。
The price Takeda is seeking for the over-the-counter business is about 20 times EBITDA, or earnings before taxes depreciation and amortisation, said the three people. The company will close the third, and likely final, bid on Monday, they said.
武田正在尋求場外業務的價格約為 20 倍 EBITDA，或稅前折舊和攤銷收益，這三個人說。他們說，該公司將在周一關閉第三個，可能是最終的出價。
The sources declined to be identified because the bidding process is private.
由於競標過程是私人的，因此拒絕識別來源。
Shortly before the Shire deal closed in 2019, Takeda Chief Executive Christophe Weber said it was unlikely the drugmaker would offload its over-the-counter (OTC) business.
在夏爾交易於 2019 年結束前不久，武田首席執行官克里斯托夫·韋伯（Christophe Weber）表示，製藥商不太可能會卸載其場外交易（OTC）業務。
But as major divestitures slowed, reaching $7.7 billion through May, the company has focused on ridding itself of non-prescription drug products, with Weber saying "we are not an OTC company."
但是隨著主要剝離業務放緩，直到 5 月份達到 77 億美元，該公司一直專注於擺脫非處方藥產品，韋伯說：「我們不是一家場外交易公司」。
The Japan OTC deal is separate from the deals Takeda has struck for two other OTC units.
日本場外交易與武田針對其他兩個場外交易單位達成的交易是分開的。
On June 11, Takeda said it would sell OTC assets in the Asia Pacific region to South Korea's Celltrion for $278 million. In April, it said it would offload European OTC and prescription products to Denmark-based Orifarm Group for about $670 million.
6 月 11 日，武田表示，該公司將以 2.08 億美元的價格將亞太地區的場外交易資產出售給韓國的賽特里恩。今年 4 月，該公司表示將以約 6.70 億美元的價格向丹麥的 Orifarm 集團卸載歐洲場外交易和處方產品。
"We view the Japan consumer healthcare business in the same light as Takeda's ongoing divestiture of global OTC assets," said Morningstar analyst Jay Lee.
晨星分析師 Jay Lee 表示：「我們對日本消費者醫療保健業務的看法與武田持續剝離全球場外交易資產的看法相同。
"It works towards the company's goal of paying down debt and also allows management to focus on Takeda's core business areas."
「它致力於實現公司償還債務的目標，並允許管理層專注於武田的核心業務領域。」
(Reporting by Junko Fujita and Rocky Swift; Editing by Stephen Coates)
（由藤田順子和洛基斯威夫特報告; 斯蒂芬·科茨編輯）
譯文內容由第三人軟體翻譯。